PTC Therapeutics (FRA:BH3) FCF Margin %: -22.16% (As of Mar. 2026)

What is PTC Therapeutics FCF Margin %?

PTC Therapeutics FRA:BH3 +0.36% 51 FCF Margin % is -22.16% as of Mar. 2026. GuruFocus rates FRA:BH3 with a GF Score™ of 51/100 and a GF Value™ of €30.17. The stock has 9 warning signs investors should review. Among 959 Biotechnology companies, PTC Therapeutics ranks better than 52.45% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. PTC Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was €-52.2 Mil. PTC Therapeutics's Revenue for the three months ended in Mar. 2026 was €235.8 Mil. Therefore, PTC Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was -22.16%.

As of today, PTC Therapeutics's current FCF Yield % is -7.39%.

The historical rank and industry rank for PTC Therapeutics's FCF Margin % or its related term are showing as below:

FRA:BH3' s FCF Margin % Range Over the Past 10 Years
Min: -127.37 Med: -46.7 Max: 23.76
Current: -62.17

During the past 13 years, the highest FCF Margin % of PTC Therapeutics was 23.76%. The lowest was -127.37%. And the median was -46.70%.

FRA:BH3's FCF Margin % is ranked better than
52.45% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs FRA:BH3: -62.17

PTC Therapeutics FCF Margin % Related Terms

PTC Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for PTC Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PTC Therapeutics FCF Margin % Chart

PTC Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

FCF Margin %

Get a 7-Day Free Trial

-62.51

-72.86

-29.75

-22.55

23.76

PTC Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
FCF Margin %	Get a 7-Day Free Trial															73.77	-34.84	-152.84	-43.46	-22.16

FRA:BH3 vs APGE, MIRM, RYTM: FCF Margin % Comparison

For the Biotechnology subindustry, PTC Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PTC Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's FCF Margin % falls into.

Save Embed

51GF Score

PTC Therapeutics Inc FRA:BH3

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

PTC Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

PTC Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	351.151	/	1477.979
	=	23.76 %

PTC Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-52.241	/	235.757
	=	-22.16 %

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of -22.16% mean?

PTC Therapeutics (FRA:BH3) has a FCF Margin % of -22.16% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on PTC Therapeutics and its competitors. According to the industry distribution chart, PTC Therapeutics ranks #456 out of 959 companies in the Biotechnology industry, placing it in the top 47.5%.

Is PTC Therapeutics' FCF Margin % too high?

PTC Therapeutics' current FCF Margin % is -22.16%. Based on the distribution chart, PTC Therapeutics ranks #456 out of 959 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PTC Therapeutics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.

How does PTC Therapeutics' FCF Margin % compare to APGE and MIRM?

According to the Biotechnology industry distribution chart, PTC Therapeutics ranks #456 out of 959 companies for FCF Margin %. This puts PTC Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Biotechnology company?

A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on PTC Therapeutics and its competitors. PTC Therapeutics's current FCF Margin % is -22.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is PTC Therapeutics stock overvalued right now?

PTC Therapeutics (FRA:BH3) has a current FCF Margin % of -22.16%. The stock's GF Value™ is €30.17, compared to a current price of €72.26 — trading 139.5% above its estimated fair value. The current FCF Margin % is -22.16%. PTC Therapeutics' overall GF Score™ is 51/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For PTC Therapeutics (FRA:BH3), the current FCF Margin % is -22.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PTC Therapeutics (FRA:BH3) Overvalued in 2026?

Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued. The current stock price of €72.26 is trading 139.5% above its estimated GF Value™ of €30.17.

Key valuation signals for FRA:BH3:

FCF Margin %: -22.16%
GF Value™: €30.17 vs. price of €72.26 (139.5% above fair value)
GF Score™: 51/100 with 9 warning signs

No single metric tells the full story. See the FRA:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PTC Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies APGE MIRM RYTM COGT SRRK SYRE PTGX TGTX CELC KYMR VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges PTCT:USA BH3:Germany

Address 500 Warren Corporate Center Drive, Warren, NJ, USA, 07059

Website https://www.ptcbio.com

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

51GF Score

Get the complete analysis for FRA:BH3

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€72.26

Price

€30.17

GF Value

View FRA:BH3 Analysis

See FCF Margin % data for all stocks →